王小琳(助理研究员,硕士生导师 )

研究方向:目前主要致力于结直肠癌生物标记物研究及靶向型抗结直肠药物的研发
2001.09.01—2005.07.01,郑州大学,化学系,理学学士
2005.09.01—2010.12.30,武汉大学,化学与分子科学学院,理学博士
主要研究经历:
2004.09—2005.07,郑州大学化学系及河南省医学科学研究所,参与国家863项目子课题中一类抗癌新药的药理学研究
2005.09—2011.02,武汉大学化学与分子科学学院,主要致力于小分子化合物与核酸的相互作用研究,先后参与大环多胺类化合物、卟啉类化合物的合成,国家创新团队子课题中量子点的化学修饰剂及在生物化学中的应用研究,核酸交联剂方向的研究等
2011.04—2013.04,美国斯坦福大学医学院,博士后,主要从事靶向型抗肝癌药物的设计研发和肝癌诊疗的生物标记物研究
2013.12—2014.10,中山大学附属第六医院,科研助理,主要从事表观遗传学领域结直肠癌生物标记物方向的研究
2014.11—至今,中山大学附属第六医院,助理研究员,研究主要围绕结直肠诊疗的生物标志物研究领域,先后承担国家自然科学基金青年科学基金项目和高校基本科研业务费中山大学青年教师培育项目各一项,参与国家973项目子课题、自然科学基金面上项目和青年科学基金项目各一项

代表性论文代表性项目荣誉

1. X. Wang#; J. Huang#; Y. Zhou; S. Yan; X. Weng; X. Wu; M. Deng; X. Zhou*, Conformational switching of G-quadruplex DNA by photoregulation. Angew Chem Int Ed Engl 2010; 49 (31), 5305-5309.(Co-first author)

2. C. Jiang#; J. Long#; B. Liu#; M. Xu; W. Wang; X. Xie; X. Wang*; M. Kuang*, miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 2017; 36 (1), 99.(Co-responding author)

3. Z. Li#; X. Wang#; H. Pan; H. Yang; X. Li; K. Zhang; H. Wang; Z. Zheng; H. Liu*; J. Wang*, Resistin promotes CCL4 expression through toll-like receptor-4 and activation of the p38-MAPK and NF-kappaB signaling pathways: implications for intervertebral disc degeneration. Osteoarthritis Cartilage 2017; 25(2):341-350. (Co-first author)

4. X. Xing#; X. Wang#; L. Xu; Y. Tai; L. Dai; X. Zheng; W. Mao; X. Xu; X. Zhou*, Light-driven conformational regulation of human telomeric G-quadruplex DNA in physiological conditions. Org Biomol Chem 2011; 9 (19), 6639-6645. (Co-first author)

5. H. C. Yu; Y. X. Luo*; X. L. Wang; L. L. Bai; P. Z. Huang; L. Wang; M. J. Huang; Y. H. Deng; J. P. Wang*, Time to lowest postoperative carcinoembryonic antigen level is predictive on survival outcome in rectal cancer. Sci Rep 2016; 6, 34131.

6. H. C. Yu; Y. X. Luo; H. Peng; X. L. Wang; Z. H. Yang; M. J. Huang; L. Kang; L. Wang; J. P*. Wang, Association of perioperative blood pressure with long-term survival in rectal cancer patients. Chin J Cancer 2016; 35, 38.

7. H. Yu; Y. Luo*; X. Wang; L. Kang; M. Huang; Y. Deng; L. Wang; J. Wang*, The effect of patterns of recurrence after radical resection of rectal cancer on long-term survival after recurrence. Natl Med J China 2016; 96 (8), 625-628.

8. L. Ma; X. Wang; T. Jia; W. Wei; M. S. Chua*; S. So, Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget 2015; 6 (28), 25390-25401.

9. W. Wei; S. Wu; X. Wang; C. K. Sun; X. Yang; X. Yan; M. S. Chua*; S. So, Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget 2014; 5 (14), 5819-5831.

10. S. Wu; Q. Cao; X. Wang; K. Cheng; Z. Cheng*, Design, synthesis and biological evaluation of mitochondria targeting theranostic agents. Chem Commun (Camb) 2014; 50 (64), 8919-8922.

11. X. Yang; H. Liu; C. K. Sun; A. Natarajan; X. Hu; X. Wang; M. Allegretta; R. D. Guttmann; S. S. Gambhir; M. S. Chua*; Z. Cheng*; S. K. So, Imaging of hepatocellular carcinoma patient-derived xenografts using (8)(9)Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials 2014; 35 (25), 6964-6971.